Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission ...
REQORSA (GPX-001) is Genprex's flagship clinical-stage gene therapy product candidate. It is designed to be administered in combination with targeted therapies and immunotherapies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The therapy works by reintroducing tumor suppressor genes into cancer cells.
Price Range: N/A (Clinical-stage, no commercial price)
Pain Points: Limited efficacy of current standard-of-care treatments for advanced lung cancers and the challenge of delivering genes effectively into tumor cells.
Solutions: Provides a novel method to reintroduce tumor suppressor genes and potentially sensitize cancer cells to targeted therapies and immunotherapies.
Target Users: Healthcare providers, oncologists, and patients diagnosed with non-small cell lung cancer or small cell lung cancer.
Supply Chain
Clinical research organizations (CROs)Contract manufacturing organizations (CMOs)Academic and medical research institutions
The ONCOPREX Delivery System is the foundational technology platform for Genprex. It is designed to encapsulate gene-expressing plasmids into nanoparticles, allowing for systemic, non-viral delivery of therapeutic genes to target cells, such as those found in solid tumors.
Price Range: N/A
Pain Points: The difficulty and toxicity associated with viral vectors in gene therapy; provides a safer, systemic approach to gene transfer.
Solutions: Offers a scalable, non-viral mechanism to deliver therapeutic genes systemically, enhancing the reach of gene therapy treatments.
Target Users: Biotechnology and pharmaceutical researchers and clinical development teams.
Supply Chain
Lipid and chemical suppliersLaboratory equipment providersSpecialized research facilities
GPX-002 is a preclinical gene therapy program targeting both Type 1 and Type 2 diabetes. Unlike the oncology pipeline, it utilizes a different gene therapy delivery system to focus on stabilizing blood glucose levels.
Price Range: N/A (Preclinical)
Pain Points: The chronic nature of diabetes and the dependency on daily exogenous insulin or current medications that do not address the underlying gene expression issues.
Solutions: Provides a novel therapeutic approach to normalize glucose metabolism through gene therapy.
Target Users: Healthcare systems and patients diagnosed with Type 1 or Type 2 diabetes.
Supply Chain
Preclinical research laboratoriesBiotech research partnersSpecialized chemical/reagent manufacturers
Aldevron (subsidiary of Danaher Corporation)NYSE:DHRUnnamed CDMO Partner (LNP-focused)4Clinics (now part of P95)University of PittsburghUniversity of MichiganNYU Langone HealthUTHealth HoustonLipid / Excipient Suppliers (generic category)
Downstream
3
AstraZeneca plcNASDAQ:AZNGabrail Cancer Center (Canton, OH)Multiple U.S. Clinical Trial Sites (oncology research network)
